Carmaux Antoine, Yvorel Cedric, Benali Karim, Romeyer Cécile, Mohammed Rayan, Vovor Jean Michel, Da Costa Antoine
Department of Cardiology, Jean Monnet University, Saint-Etienne, France.
J Cardiovasc Electrophysiol. 2025 Jun;36(6):1244-1252. doi: 10.1111/jce.16650. Epub 2025 Mar 24.
Different ablation strategies have been developed for persistent atrial fibrillation (PeAF), but early management is still controversial. In the clinical setting of PeAF, the safety and efficacy of early Marshall plan have not yet been fully studied.
Our prospective cohort study sought to: (1) assess the safety and feasibility of the thermal Marshall plan (MPA) approach as a first-line therapy in PeAF patients; (2) evaluate its long-term sinus rhythm maintenance efficacy; (3) identify the long-term predictive factors of AF recurrence in PeAF patients after MPA approach.
Between January 2020 and December 2023, 118 PeAF patients were selected for first intent Marshall plan ablation (MPA). Marshall vein failure occurred in 9/118 patients (7.6%). Accordingly, 109 patients who underwent MPA as first-line therapy were included. After the blanking period of 3 months, 62/109 patients were in sinus rhythm (SR) (57%), 33/109 were in AF (30.2%), 8/109 were in left atrial flutter (AFL) (7.3%), and six were in right AFL (5.5%). Re-ablation was performed in 4/33 patients (12.1%) and cardioversion in 29/33 (87.9%) for patients in AF at 3 months after healing. All patients in AFL at 3 months were re-ablated and all recovered SR. At 12 months postablation, two patients were lost to follow-up (1.8%), 94/107 (87.8%) were in SR and 13/107 had AF recurrence (12.2%). At 21 ± 11 months postablation, 81/107 (75.7%) were in SR at the last control, and 26/107 (24.3%) had AF recurrence. The ablation procedure ratio was 1.17 (109 primo ablation, 18 re-ablation). The only predictive factors of late AF recurrence after first-line PeAF MPA were both left atrial dilatation and low left ventricular ejection fraction (LVEF).
This real-life prospective cohort study showed that de novo MPA in PeAF is feasible, relatively safe, and associated with a high rate of freedom from arrhythmia recurrence during long-term follow-up. The percentage of patients remaining in SR during long-term follow-up was close to 76%. The only predictive MPA failure factors were both left atrial dilatation and low LVEF.
针对持续性心房颤动(PeAF)已开发出不同的消融策略,但早期管理仍存在争议。在PeAF的临床环境中,早期马歇尔计划的安全性和有效性尚未得到充分研究。
我们的前瞻性队列研究旨在:(1)评估热马歇尔计划(MPA)方法作为PeAF患者一线治疗的安全性和可行性;(2)评估其长期窦性心律维持疗效;(3)确定MPA方法后PeAF患者房颤复发的长期预测因素。
2020年1月至2023年12月期间,118例PeAF患者被选作初次马歇尔计划消融(MPA)。118例患者中有9例(7.6%)出现马歇尔静脉失败。因此,纳入109例接受MPA作为一线治疗的患者。在3个月的空白期后,109例患者中有62例(57%)处于窦性心律(SR),33例(30.2%)处于房颤状态,8例(7.3%)处于左房扑动(AFL),6例(5.5%)处于右房扑动。在愈合后3个月时,房颤患者中有4例(12.1%)进行了再次消融,29例(87.9%)进行了复律。3个月时处于AFL的所有患者均接受了再次消融,所有患者均恢复为SR。消融术后12个月,2例患者失访(1.8%),107例中有94例(87.8%)处于SR,13例(12.2%)房颤复发。消融手术比例为1.17(109例初次消融,18例再次消融)。一线PeAF MPA后晚期房颤复发的唯一预测因素是左房扩大和左室射血分数(LVEF)降低。
这项真实世界的前瞻性队列研究表明,PeAF患者初次MPA是可行的,相对安全,且在长期随访中与心律失常复发的高自由度相关。长期随访中维持在SR的患者百分比接近76%。MPA失败的唯一预测因素是左房扩大和低LVEF。